Clinical implication of CD166 expression in salivary gland tumor
CD166 is a glycoprotein of immunoglobulin superfamily of adhesion molecules which is overexpressed in many tumors. However, no published literature was found concerning CD166 expression in salivary gland tumor. The purpose of this study was to examine the CD166 expression in the salivary gland tumor by an immunohistochemical approach, to examine the clinical implication of this marker in the prognosis and diagnosis of the salivary gland tumor. In this study, 45 samples of salivary tumors from Khalili Hospital archive including 15 cases of pleomorphic adenoma, 16 cases of mucoepidermoid carcinoma, 14 cases of adenoid cystic carcinoma, and 15 normal salivary glands were selected for immunohistochemistry (IHC) method staining for CD166. CD166 immunoreactivity in malignant tumors (adenoid cystic carcinoma (ACC) and mucoepidermoid carcinoma (MEC)) (56.7 ± 14.05) was significantly higher than that of pleomorphic adenoma (PA) (34.3 ± 17.07) (P < 0.000) and higher in the PA than normal salivary gland (13.2 ± 12.1) (P = 0.001). CD166 expression was significantly higher in the high-grade tumors (90.3 ± 11.07) compared to low-grade (65.11 ± 27.08) malignant tumors (P = 0.002). CD166 expression showed a significant association with tumor size and the clinical stage (P < 0.001). In conclusion, an overexpression of CD166 was detected in the benign and malignant salivary gland tumors and its expression in the malignant tumor was associated with the aggressive behavior and tumor progression. For this reason, CD166 may be one of the potential biomarkers for predicting tumor behavior in the prognosis of this disease.
KeywordsSalivary gland tumor Pleomorphic adenoma Adenoid cystic carcinoma Mucoepidermoid carcinoma CD166
The authors thank the Vice-Chancellery of Shiraz University of Medical Sciences for supporting this research (Grant #92-01-03-6495). This manuscript is based on the thesis of Shahab Ahmadi for partial fulfillment of DDS degree. The authors are grateful to Dr. Sh. Hamedani (DDS, MSC) for his suggestions and editorial assistance, and also, thanks to Dr. M. Vossoughi of the Dental Research Development Center of the Dental School, for the statistical analysis.
- 10.Tuyns AJ, Estève J, Raymond L, Berrino F, Benhamou E, Blanchet F, et al. Cancer of the larynx/hypopharynx, tobacco and alcohol: IARC international case–control study in Turin and Varese (Italy), Zaragoza and Navarra (Spain), Geneva (Switzerland) and Calvados (France). Int J Cancer. 1988;41(4):483–91.CrossRefPubMedGoogle Scholar
- 33.Yamada K. Comparative expression of E-cadherin, α and β-catenin in salivary gland tumors. In: Namba M, editor.: Acta Histochem Cytochem; 1999. p. 305–10.Google Scholar
- 36.Wang NS, Wei M, Ma WL, Meng W, Zheng WL. Knockdown of CD44 enhances chemosensitivity of acute myeloid leukemia cells to ADM and Ara-C. Tumour Biol. 2013.Google Scholar